IBN is thrilled to announce the release of the latest episode of The Bell2Bell Podcast, featuring an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio Inc. The podcast was recorded live from the Alzheimer’s Association International Conference 2024 (AAIC) in Philadelphia.
During the interview, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 3 Parkinson’s study of its lead drug candidate, buntanetap. The study has shown promising results, indicating that buntanetap has the potential to significantly improve the quality of life for Parkinson’s patients.
The scientific community has been reacting positively to the data, recognizing its potential impact on the future of neurodegenerative disease treatment. Dr. Maccecchini discusses the importance of sharing these findings live from AAIC, one of the most prestigious events in Alzheimer’s and Parkinson’s research.
In addition to the Phase 3 study, Dr. Maccecchini also shares Annovis Bio’s strategic plans moving forward. This includes potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.
The Bell2Bell Podcast, hosted by Stuart Smith, provides informative updates and exclusive interviews with executives operating in fast-moving industries. It is part of IBN’s ongoing efforts to provide specialized content distribution via widespread syndication channels.
To listen to the latest episode of The Bell2Bell Podcast and subscribe for future podcasts, visit the official website at https://podcast.bell2bell.com.
Annovis Bio Inc., headquartered in Malvern, Pennsylvania, is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease and Parkinson’s disease. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
IBN, a multifaceted communications organization, has been connecting public companies to the investment community for over 18 years. With a collective audience of millions of social media followers, IBN’s branded network of highly influential properties continues to expand, serving a growing base of client-partners.
For more information about Annovis Bio Inc., please visit their website at www.annovisbio.com and follow them on LinkedIn, YouTube, and X.
Please see the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN.
Disclaimer: This release contains forward-looking statements, and readers are advised to review the various risks and uncertainties identified in the release and the company’s SEC filings. The company’s actual results may differ materially from those indicated in the forward-looking statements.